July 2022 updates to the website
20 July 2022
The website has now been updated following July's LSCMMG
The following guidelines have been added/updated:
Primary care PPI review guideline - added
Varenicline position statement - updated
Asthma desktop guideline - added
Amiodarone shared care guideline - updated
Lipid pathway guideline - added
The following Items will be updated and added to the website following the next Strategic Commissioning Committee (SCC) Meeting:
Paliperidone 6 monthly - As a treatment option for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1-monthly or 3-monthly paliperidone palmitate injectable products
Romosozumab - Severe osteoporosis (NICE TA791)
Filgotinib - For treating moderately to severely active ulcerative colitis (NICE TA792)
Faricimab - For treating diabetic macular oedema (NICE TA799)
Faricimab - For treating wet age-related macular degeneration (NICE TA800)